Tofacitinib and Hepatic Impairment Management
Tofacitinib is contraindicated in severe hepatic impairment (Child-Pugh C), requires dose reduction to 5 mg once daily in moderate hepatic impairment (Child-Pugh B), and needs no adjustment in mild hepatic impairment (Child-Pugh A). 1, 2
Contraindications by Hepatic Function
- Severe hepatic impairment (Child-Pugh C): Do not use tofacitinib 1, 2
- Moderate hepatic impairment (Child-Pugh B): Reduce dose to 5 mg once daily regardless of indication 1, 2
- Mild hepatic impairment (Child-Pugh A): No dose adjustment required 1
Specific Dosing Adjustments
For patients with moderate hepatic impairment, apply these reductions 2:
- If taking 10 mg twice daily → reduce to 5 mg once daily
- If taking 5 mg twice daily → reduce to 5 mg once daily
- If taking 22 mg once daily (extended-release) → reduce to 11 mg once daily
- If taking 11 mg once daily (extended-release) → reduce to 5 mg once daily
In pediatric patients with polyarticular course juvenile idiopathic arthritis and moderate hepatic impairment 2:
- If taking 3.2 mg twice daily → reduce to 3.2 mg once daily
- If taking 4 mg twice daily → reduce to 4 mg once daily
- If taking 5 mg twice daily → reduce to 5 mg once daily
Liver Function Monitoring Protocol
Monitor transaminases at 1 month, 3 months, then every 3 months during treatment. 1 This structured monitoring schedule is critical because tofacitinib undergoes approximately 70% hepatic metabolism via CYP3A4 2.
The 2025 expert consensus emphasizes considering dose adjustments in patients with significant hepatic impairment as part of individualized treatment planning 3, though the specific Child-Pugh-based recommendations remain the standard approach.
Pharmacokinetic Rationale
Research demonstrates that moderate hepatic impairment increases tofacitinib AUC by approximately 65% and Cmax by 49% 4, which directly supports the dose reduction recommendations in the FDA label. Tofacitinib clearance is approximately 70% hepatic metabolism (primarily CYP3A4) and 30% renal excretion 2, making hepatic function critical to drug exposure.
Critical Clinical Pitfalls
Do not use disease activity scores heavily weighted on acute phase reactants (like DAS28) for monitoring treatment response, as tofacitinib reduces CRP and ESR independently of clinical improvement 1. Use joint count-based measures instead.
Be aware that one case report documented severe drug-induced liver injury requiring transplantation with tofacitinib 5, though this is rare. The patient recovered after drug discontinuation and supportive care, highlighting the importance of regular transaminase monitoring.
Drug Interactions Affecting Hepatic Metabolism
When strong CYP3A4 inhibitors (ketoconazole) or moderate CYP3A4 plus strong CYP2C19 inhibitors (fluconazole) are co-administered, reduce tofacitinib dose by 50% 3, 1, 2. Conversely, rifampicin increases hepatic metabolism, potentially requiring dose increases 3, 1.